Prognostic impact of telomerase activity in patients with neuroblastoma.

  • Authors:
    • C Nozaki
    • K Horibe
    • H Iwata
    • Y Ishiguro
    • M Hamaguchi
    • M Takahashi
  • View Affiliations

  • Published online on: August 1, 2000     https://doi.org/10.3892/ijo.17.2.341
  • Pages: 341-346
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neuroblastoma is one of the most common malignant neoplasms occurring among children. The prognosis for this disease is strongly associated with age, disease stage, histology, and some biologic features. It has been reported that telomerase, a ribonucleoprotein enzyme, which maintains the telomere length in immortal cells, is related to disease stage and other biologic features. The purpose of this study was to evaluate the prognostic value of telomerase activity compared to TrkA expression in 65 patients with neuroblastoma. Telomerase activity and TrkA expression were examined in tissue samples collected between 1980 and 1994 from 65 patients by polymerase chain reaction-based telomerase activity. TrkA expression was examined by immunoblotting using a rabbit anti-gp140 proto-trk polyclonal antibody. Low telomerase activity was found in 22 of 30 (73.3%) patients with Stages 1, 2, or 4S neuroblastomas; 7 of 13 (53.8%) with Stage 3; and 8 of 22 (36.3%) with stage 4; no telomerase activity was detected in 7 of 22 (31.8%) patients with Stage 4 neuroblastoma. The 5-year event-free survival (EFS) rate was 86.5% for patients with low telomerase activity, while it was 53.8% for patients with high telomerase activity. By the combination of telomerase activity and TrkA expression, the 5-year EFS rate was highest among patients with a high TrkA expression and a low or non-existent telomerase activity (91.7%), and it was lowest among patients with a low TrkA expression and a high telomerase activity (29.6%). Thus, it appears that telomerase activity would be a useful prognostic factor for neuroblastoma, especially when used in combination with the TrkA expression.

Related Articles

Journal Cover

Aug 2000
Volume 17 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nozaki C, Horibe K, Iwata H, Ishiguro Y, Hamaguchi M and Takahashi M: Prognostic impact of telomerase activity in patients with neuroblastoma.. Int J Oncol 17: 341-346, 2000
APA
Nozaki, C., Horibe, K., Iwata, H., Ishiguro, Y., Hamaguchi, M., & Takahashi, M. (2000). Prognostic impact of telomerase activity in patients with neuroblastoma.. International Journal of Oncology, 17, 341-346. https://doi.org/10.3892/ijo.17.2.341
MLA
Nozaki, C., Horibe, K., Iwata, H., Ishiguro, Y., Hamaguchi, M., Takahashi, M."Prognostic impact of telomerase activity in patients with neuroblastoma.". International Journal of Oncology 17.2 (2000): 341-346.
Chicago
Nozaki, C., Horibe, K., Iwata, H., Ishiguro, Y., Hamaguchi, M., Takahashi, M."Prognostic impact of telomerase activity in patients with neuroblastoma.". International Journal of Oncology 17, no. 2 (2000): 341-346. https://doi.org/10.3892/ijo.17.2.341